Tamoxifen as an anti-tumour agent: effect on oestrogen binding.
J Endocrinol, 1976/2;68(02):297-303.
PMID: 176295
Impact factor: 4.669
Abstract
Tamoxifen (ICI 46,474) has been shown to possess anti-tumour properties in the dimethylbenz(a)anthracene (DMBA)-induced rat mammary carcinoma model. During tamoxifen therapy the binding of [3H]oestradiol in vivo to uterine (P less than 0-001), vaginal (P less than 0 X 01) and tumour (P less than 0-001) tissues was significantly reduced. Tamoxifen therapy was without effect on the binding of [3H]oestradiol in heart tissue. The determination of specific oestrogen-binding components in vitro was significantly reduced (P less than 0-01) in tumours from tamoxifen-treated rats and tamoxifen inhibited the binding of [3H]oestradiol to 8S oestrogen-binding components, derived from rat uteri and DMBA-induced tumours, in vitro.
MeSH terms
9,10-Dimethyl-1,2-benzanthracene; Animals; Estradiol; Female; Mammary Neoplasms, Experimental; Rats; Receptors, Cell Surface; Stilbenes; Tamoxifen; Uterus; Vagina
More resources
EndNote: Download